靶向PPAR-γ可逆转肝细胞癌对免疫检查点阻断的肿瘤适应
该研究通过抗PD-L1治疗的免疫健全小鼠连续原位植入肝细胞癌细胞,建立两种免疫治疗耐药肝细胞癌模型,采用单细胞RNA测序、基因组和免疫分析进行探究。发现肿瘤细胞内在的PPARγ上调通过转录激活VEGF-A产生,驱动髓源性抑制细胞扩增和CD8+ T细胞功能障碍;选择性PPARγ拮抗剂可逆转免疫抑制微环境并使肿瘤对抗PD-L1治疗重新敏感。在帕博利珠单抗耐药的肝细胞癌患者中,40%(6/15)显示肿瘤PPARγ诱导,且基线PPARγ表达较高与抗PD-(L)1治疗患者生存较差相关。
要点
- 抗PD-L1耐药肿瘤在免疫健全小鼠中比亲本肿瘤生长大10倍以上,无明显的基因改变。
- 肿瘤细胞内在PPARγ上调通过转录激活VEGF-A驱动MDSC扩增和CD8+ T细胞功能障碍。
- 选择性PPARγ拮抗剂可逆转免疫抑制微环境并使肿瘤对抗PD-L1治疗重新敏感。
核心结论
- 肿瘤细胞通过PPARγ/VEGF-A介导的肿瘤微环境免疫抑制逃避免疫检查点阻断,为克服肝细胞癌免疫治疗耐药提供了策略。
研究设计与样本
- 通过抗PD-L1治疗的免疫健全同系小鼠连续原位植入肝细胞癌细胞,建立两种免疫治疗耐药肝细胞癌模型。
- 采用单细胞RNA测序、基因组和免疫分析对模型进行探究。
- 通过慢病毒介导的敲低和药理学抑制研究关键信号通路。
- 通过II期帕博利珠单抗试验(NCT03419481)的肝细胞癌肿瘤活检单细胞RNA测序分析进行验证。
主要发现
- 抗PD-L1耐药肿瘤在免疫健全小鼠中比亲本肿瘤生长大10倍以上,但在免疫缺陷小鼠中未观察到此现象,且无明显的基因改变。
- 耐药肿瘤伴随瘤内髓源性抑制细胞(MDSC)积累、细胞毒性向耗竭CD8+ T细胞转化及排斥。
- 肿瘤细胞内在的PPARγ上调转录激活VEGF-A产生,驱动MDSC扩增和CD8+ T细胞功能障碍。
- 选择性PPARγ拮抗剂触发免疫抑制向免疫刺激的肿瘤微环境转化,并在原位和自发肝细胞癌模型中使肿瘤对抗PD-L1治疗重新敏感。
- 40%(6/15)的帕博利珠单抗耐药肝细胞癌患者显示肿瘤PPARγ诱导;基线PPARγ表达较高与多种癌症类型中抗PD-(L)1治疗患者生存较差相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Therapy-induced tumour microenvironment (TME) remodelling poses a major hurdle for cancer cure. As the majority of patients with hepatocellular carcinoma (HCC) exhibits primary or acquired resistance to antiprogrammed cell death (ligand)-1 (anti-PD-[L]1) therapies, we aimed to investigate the mechanisms underlying tumour adaptation to immune-checkpoint targeting. DESIGN: Two immunotherapy-resistant HCC models were generated by serial orthotopic implantation of HCC cells through anti-PD-L1-treated syngeneic, immunocompetent mice and interrogated by single-cell RNA sequencing (scRNA-seq), genomic and immune profiling. Key signalling pathway was investigated by lentiviral-mediated knockdown and pharmacological inhibition, and further verified by scRNA-seq analysis of HCC tumour biopsies from a phase II trial of pembrolizumab (NCT03419481). RESULTS: Anti-PD-L1-resistant tumours grew >10-fold larger than parental tumours in immunocompetent but not immunocompromised mice without overt genetic changes, which were accompanied by intratumoral accumulation of myeloid-derived suppressor cells (MDSC), cytotoxic to exhausted CD8+ T cell conversion and exclusion. Mechanistically, tumour cell-intrinsic upregulation of peroxisome proliferator-activated receptor-gamma (PPARγ) transcriptionally activated vascular endothelial growth factor-A (VEGF-A) production to drive MDSC expansion and CD8+ T cell dysfunction. A selective PPARγ antagonist triggered an immune suppressive-to-stimulatory TME conversion and resensitised tumours to anti-PD-L1 therapy in orthotopic and spontaneous HCC models. Importantly, 40% (6/15) of patients with HCC resistant to pembrolizumab exhibited tumorous PPARγ induction. Moreover, higher baseline PPARγ expression was associated with poorer survival of anti-PD-(L)1-treated patients in multiple cancer types. CONCLUSION: We uncover an adaptive transcriptional programme by which tumour cells evade immune-checkpoint targeting via PPARγ/VEGF-A-mediated TME immunosuppression, thus providing a strategy for counteracting immunotherapeutic resistance in HCC.
引用
- Xiong Z, Chan SL, Zhou J, et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023. PMID: 37019619. doi:10.1136/gutjnl-2022-328364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。